Meeting
2015 ASCO Annual Meeting
UCART19, an allogeneic “off-the-shelf” adoptive T-cell immunotherapy against CD19+ B-cell leukemias.
Authors
Julianne Smith
Cellectis, Paris, France
Julianne Smith , Laurent Poirot , Brian Philip , Cecile Schiffer-Mannoui , Sophie Derniame , Hong Zhan , Sian Stafford , Stephan Reynier , Sylvain Arnould , Agnes Gouble , Waseem Qasim , Karl Peggs , Martin Pule , David Sourdive
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics and Translational Research
Sub Track
Immunotherapy and Biologic Therapy
Citation
J Clin Oncol 33, 2015 (suppl; abstr 3069)
DOI
10.1200/jco.2015.33.15_suppl.3069
Abstract #
3069
Poster Bd #
395
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Preclinical evaluation of targeting PRAME with TCR mimic CAR T cells in AML.
First Author: Danielle Kirkey
Poster
2023 ASCO Annual Meeting
Updated clinical results of first-in-human study of CD19/BCMA dual-targeting fast CAR-T GC012F for patients with relapsed/refractory B-cell non-Hodgkin’s lymphoma.
First Author: Xinfeng Chen
Poster
2020 ASCO Virtual Scientific Program
Eradication of medulloblastoma by NKG2D-specific CAR T-cells.
First Author: Hong-jiu Dai
Poster
2018 ASCO Annual Meeting
Clinical anti-lymphoma activity and toxicity of T cells expressing a novel anti-CD19 chimeric antigen receptor with fully-human variable regions.
First Author: Jennifer N. Brudno